foxnews : declared in Takeda and NY biotech Ovid ink rare drug development pact
This was collected by Lucy William
follow all the new news about Drug
image uploaded by "foxnews" site
A new drug is offering hope for the family of a little girl whose genetic defect causes mobility issues similar to that of polio and amyotrophic lateral sclerosis (ALS).Four-year-old Lexi Pacini, of Colorado Springs, was diagnosed with type 2 spinal muscular atrophy (SMA) as a toddler.The rare disease is marked by the absence of a gene that codes protein signals from motor neurons to muscles, and it leads muscles to weaken to the point of atrophy.
about the details read more from here
image uploaded by "fiercebiotech" site
Takeda, pushing on with its R&D metamorphoses, has signed a research deal and collab with New York's private biotech Ovid that will see the small company work on the Japanese pharma's new candidate for a rare form of childhood epilepsy.The deal is a little different that the usual pact; instead of Takeda buying into a promising med from Ovid, it is Ovid who will help out on the Osaka-based company's TAK-935, a selective CH24H inhibitor, in rare pediatric epilepsies.The med has already been under a phase 1 test through Takeda, and is now set to move into phase 1b/2a trials in rare epileptic encephalopathies.
about the details read more from here
image uploaded by "businessinsider" site
In drug development, the typical trajectory for a small biotech company is to develop a drug, then find a big-pharma partner to help fund trials and get the drug onto the market if it gets approved.But a partnership announced today is bucking that trend.Japan's Takeda Pharmaceuticals is teaming up with New York-based biotech company Ovid Therapeutics to co-develop TAK-935, a drug meant to treat rare epilepsy disorders in children.
about the details read more from here
We will quote to you the news of the best health sites Like : "foxnews" and the most famous medical experts :
daily : 2017-01-18 & on time : 13:28
follow all the new news about Drug
according to
4-year-old who was deemed 'lazy' finds hope in new drug that treats rare disease
image uploaded by "foxnews" site
A new drug is offering hope for the family of a little girl whose genetic defect causes mobility issues similar to that of polio and amyotrophic lateral sclerosis (ALS).Four-year-old Lexi Pacini, of Colorado Springs, was diagnosed with type 2 spinal muscular atrophy (SMA) as a toddler.The rare disease is marked by the absence of a gene that codes protein signals from motor neurons to muscles, and it leads muscles to weaken to the point of atrophy.
about the details read more from here
Takeda and NY biotech Ovid ink rare drug development pact
image uploaded by "fiercebiotech" site
Takeda, pushing on with its R&D metamorphoses, has signed a research deal and collab with New York's private biotech Ovid that will see the small company work on the Japanese pharma's new candidate for a rare form of childhood epilepsy.The deal is a little different that the usual pact; instead of Takeda buying into a promising med from Ovid, it is Ovid who will help out on the Osaka-based company's TAK-935, a selective CH24H inhibitor, in rare pediatric epilepsies.The med has already been under a phase 1 test through Takeda, and is now set to move into phase 1b/2a trials in rare epileptic encephalopathies.
about the details read more from here
Ovid Therapeutics partners with Takeda on rare epilepsy drug
image uploaded by "businessinsider" site
In drug development, the typical trajectory for a small biotech company is to develop a drug, then find a big-pharma partner to help fund trials and get the drug onto the market if it gets approved.But a partnership announced today is bucking that trend.Japan's Takeda Pharmaceuticals is teaming up with New York-based biotech company Ovid Therapeutics to co-develop TAK-935, a drug meant to treat rare epilepsy disorders in children.
about the details read more from here
Comments
Post a Comment